(redirected from Femara)
Also found in: Medical.
Related to Femara: tamoxifen


A nonsteroidal drug, C17H11N5, that inhibits the enzyme aromatase and is used to treat breast cancer in postmenopausal women.

[le-, of unknown origin + alteration of triazole.]


(Pharmacology) an anti-oestrogen drug used in the treatment of breast cancer in post-menopausal women. Also called (trademark): Femara
References in periodicals archive ?
Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec/Glivec), ciclosporin (Neoral/Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others.
"Hormonal medications such as tamoxifen and aromatase inhibitors (Arimidex, Aromasin, and Femara) interfere with estrogen and prevent it from activating cancer cells.
As the Head of Oncology Clinical Development, she directed the clinical programs leading to successful regulatory approvals for EXJADE, GLIVEC, FEMARA, AFINITOR, RYDAPT, JAKAVI and FARIDAK among others.
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial.
While at Novartis, Boehm oversaw commercial launches of various oncology brands in the US and globally, such as Femara, Zometa and Glivec.
The overall results in the two treatment arms were roughly similar, except for the striking benefit seen with everolimus (Afinitor) plus letrozole (Femara) in the chemotherapy-naive patents; 15 patients in each arm had not received any chemotherapy before entering the study In this subgroup, among the patients who received conventional hormonal therapy, the objective response rate was 43% and progression-free survival was 6.6 months.
Novartis has released the Kisqali Femara Co-Pack (ribociclib and letrozole tablets), a treatment for metastatic breast cancer in postmenopausal women, to U.S.
Novartis received approval from the FDA for Kisqali Femara Co-Pack (ribociclib tablets; letrozole tablets) for the treatment of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in postmenopausal women.
The global breast cancer therapeutics market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug classes - brand name (chemical name) such as antimetabolites - Gemzar (gemcitabine), aromatase inhibitors - Afinitor (everolimus), Arimidex (anastrozole), Aromasin (exemestane), Femara (leterozole), Ibrance (palbociclib); Her2 Inhibitors - Herceptin (trastuzumab), Kadcyla (ado-trastuzumab emtansine), Perjeta (pertuzumab), Tykerb (lapatinib); Hormone receptors - Fareston, Faslodex, Zoladex; and Mitotic inhibitors - Halaven (eribulin), Ixempra (ixabepilone), Taxotere (docetaxel), and forecasts growth trends (CAGR% - 2016 to 2020).
Hormonal therapy consisted of Femara for 3 years and Arimidex for 4 years.
Group (A) received letrozole (Femara; Novartis) with a dose of 2.5 mg/day given from day 5-9 of the menstrual cycle, for 3 successive cycles.
But letrozole (Femara, a breast cancer drug) may be a better choice.